The Eshelman Institute leverages therapeutic strategy to cultivate translational science at UNC.
The Eshelman Institute drives therapeutic strategy, creates enabling drug discovery infrastructure, and funds pre-clinical projects to create partner-ready assets for unmet needs in oncology, neuroscience, and infectious disease. The Institute de-risks cutting-edge innovations with an early-stage pipeline focused on novel target discovery, target validation, and platform technologies. Strategic investment and translational initiatives are designed to move assets from discovery to preclinical and early development studies. Robust project management, diligence, and support from industry advisors facilitate asset delivery across the translational gap.
Our strategic therapeutic focus areas are neuroscience, oncology, and infectious disease.